Home > HP (current issue) > News and features / News Centre | Search

PJ Online homeHospital Pharmacist
2006;13:198
June 2006

Hospital Pharmacist back issues

News summary


Prescribing will increase pharmacists’ role in the reporting of adverse drug reactions

Pharmacists' roles in reporting adverse drug reactions (ADRs) will become increasingly important as the part they play in prescribing grows, according to Vivienne Nathanson, head of ethics and science at the British Medical Association. She was speaking at the launch of a BMA report into ADRs.

The BMA report, “Reporting adverse drug reactions — a guide for health care professionals”, warns that the increased availability of general sale list medicines may be making it harder to identify ADRs. Charles George, chairman of the BMA’s board of science, says in the foreword: “Increased private sector availability from sources such as newsagents, supermarkets and the internet can result in OTC medications, including herbal remedies, being purchased with little or no support or control from doctors or pharmacists.”

Commenting on the report, Anthony Cox, pharmacovigilance pharmacist at the West Midlands Centre for Adverse Drug Reaction Reporting, said: “Following the admission of pharmacists to the yellow card scheme it is gratifying to see that the profession has performed admirably, now accounting for about 18 per cent of reports.”

Hemant Patel, President of the Royal Pharmaceutical Society, said that, as well as increasing the reporting of ADRs, more needs to be done to prevent them occurring in the first place. “Health care professionals, particularly in primary care, need to devote more efforts to identifying adverse drug reactions before they result in a patient being admitted to hospital,” he said. Medicines use reviews allow pharmacists to identify ADRs before there is a serious risk to the health of the patient, he added. “Patient safety could further be improved if pharmacists were able to access more information about a patient’s condition.”

In a separate development, researchers have found that the costs of non-compliance with medicines are about £8bn in England (Journal of Medical Economics 2006; 9: 27-44). Researchers found that 392,000 acute admissions in England resulted from ADRs, accounting for about 0.7 per cent of the Department of Health budget (based on 2004 figures). Wastage of medicines was estimated at 2.3 per cent of total medication costs.

Back to Top


©The Pharmaceutical Journal